论文部分内容阅读
接受Cyclosporin A(以下简称CyA)治疗的脏器移植患者并用红霉素时,可出现CyA的毒性反应。这被认为是由于并用红霉素可使CyA的血药浓度升高所致。关于其机理,有人推测可能是红霉素阻碍CyA的代谢。如果是这一机理所致,那末在静注CyA时也发生上述两药的药物相互作用。为探明其机理,作者进行了有关研究。试验在需长期接受CyA治疗的6名肾移植患者中进行。在给与红霉素(500mg,4次/日)和不给与红霉素的两组受试者中,分别以口服(5mg/kg)或恒速静注(在3～6小
Cyclosporin A (hereinafter referred to as CyA) treatment of organ transplant patients with erythromycin, CyA can occur toxicity. This is believed to be due to the combination of erythromycin and CyA can cause increased plasma concentrations. Regarding its mechanism, it is speculated that erythromycin may block the metabolism of CyA. If this mechanism is due, then the drug-drug interaction of the two drugs also occurs when CyA is administered intravenously. To find out its mechanism, the author carried out the relevant research. The trial was performed on 6 renal transplant patients who required long-term CyA treatment. Of the two groups of subjects given erythromycin (500 mg, 4 times / day) and those not given erythromycin, they were orally administered (5 mg / kg) or intravenously